Parkville, MO, United States
Parkville, MO, United States

University Park is the postal address used by Pennsylvania State University for its flagship campus in State College and adjacent College Township, Pennsylvania. It is not an incorporated community but exists as a postal address, with the accompanying zip code of 16802, for ease of mail delivery and to distinguish on-campus from off-campus addresses. Almost all of University Park sits within the borough of State College; the northeastern part of campus is within College Township. The campus post office was designated "University Park, Pennsylvania" in 1953 by Penn State president Milton Eisenhower, after what was then Pennsylvania State College was upgraded to university status.University Park sits within the State College Metropolitan Statistical Area , which encompasses all of Centre County, Pennsylvania. The ZCTA for ZIP code 16802 had a population of 12,764 at the 2010 census.The campus is served by the Penn State University Police.Federally, the University Park campus is part of Pennsylvania's 5th congressional district, represented by Republican Glenn "G.T." Thompson, elected in 2008. Wikipedia.

Time filter

Source Type

Agency: Cordis | Branch: H2020 | Program: MSCA-RISE | Phase: MSCA-RISE-2015 | Award Amount: 891.00K | Year: 2016

Our proposal aims to carry out a systematic interdisciplinary study of carbon-based nanomaterials, such as: carbon fluoroxide nanoparticles, carbon nanotubes, graphene and nanodiamonds for advanced theranostic application. Their uptake efficiency and specific localization in biological cells depending on intentionally designed surface chemistry will be studied in details. Extremely rich physico-chemical properties of the carbon-based nanomaterials will allow their application as multi-modal bio-imaging agents. Indeed, in addition to their well-known remarkable luminescent properties, two original bio-imaging approaches based on photo-induced electrical and acoustic effects will be developed in frames of our project. Moreover, the photo-exciting sources used for the bio-imaging purpose will be simultaneously used for therapy of cancer cells and tissues containing the carbon nanomaterials. Strongly complementary research experiences of the international partners involved in this project as well as high degree of cooperative integration between them will allow a deep scientific study of the theranostic potential of the carbon nanomaterials. Finally, active participation of the Ray Technique Ltd industrial company in the project consortium will allow building of strategies for economic realizations of the innovative achievements succeeded by the partners.

A series of resorcylic acid macrolactams, nitrogen analogues of the naturally occurring macrolactone radicicol, have been prepared by chemical synthesis and evaluated as inhibitors of heat shock protein 90 (Hsp90), an emerging attractive target for novel cancer therapeutic agents. The synthesis involves, as key steps, ring opening of an isocoumarin intermediate, followed by a ring-closing metathesis reaction to form the macrocycle. Subsequent manipulation of the ester group into a range of amides allows access to a range of new macrolactams following deprotection of the two phenolic groups. These new resorcylic acid lactams exhibit metabolic stability greater than that of related lactone counterparts, while co-crystallization of three macrolactams with the N-terminal domain ATP site of Hsp90 confirms that they bind in a similar way to the natural product radicicol and to our previous synthetic lactone analogues. Interestingly, however, in the case of the N-benzylamide, additional binding to a hydrophobic pocket of the protein was observed. In biological assays, the new macrocyclic lactams exhibit a biological profile equivalent or superior to that of the related lactones and show the established molecular signature of Hsp90 inhibitors in human colon cancer cells.

Previous studies have demonstrated poor sensitivity of guideline weight monitoring in predicting clinical deterioration of heart failure (HF). This study aimed to evaluate patterns of remotely transmitted daily weights in a high-risk HF population and also to compare guideline weight monitoring and an individualized weight monitoring algorithm. Consenting, consecutive, high-risk patients were provided with a mobile phone-based remote weight telemonitoring device. We aimed to evaluate population vs. individual weight variability, weight patterns pre- and post-events of clinical deterioration of HF, and to compare guideline weight thresholds with the HeartPhone algorithm in terms of sensitivity and specificity for such events. Of 87 patients recruited and followed for an average of 23.9 ± 12 weeks, 19 patients experienced 28 evaluable episodes of clinical deterioration of HF. Following a post-discharge decline, the population average weight remained stable for the follow-up period, yet the 7-day moving average of individual patients exceeded 2 kg in three-quarters of patients. Significant increases in weight were observed up to 4 days before HF events. The HeartPhone algorithm was significantly more sensitive (82%) in predicting HF events than guideline weight thresholds of 2 kg over 2-3 days (21%) and a 'rule of thumb' threshold of 1.36 kg over 1 day (46%). An individualized approach to weight monitoring in HF with the HeartPhone algorithm improved prediction of HF deterioration. Further evaluation of HeartPhone with and without other biomarkers of HF deterioration is warranted.

Molloy E.S.,Park University | Calabrese L.H.,Cleveland Clinic
Arthritis and Rheumatism | Year: 2012

Objective To evaluate the association of progressive multifocal leukoencephalopathy (PML) with immunosuppressive therapy for autoimmune rheumatic diseases (ARDs). Methods A Freedom of Information Act request was submitted for all cases of PML within the Food and Drug Administration Adverse Event Reporting System database. ARD cases were selected for further analysis. Results A total of 34 confirmed cases of PML in the setting of ARDs were identified: 17 had systemic lupus erythematosus, 10 had rheumatoid arthritis, 4 had vasculitis, and 3 had dermatomyositis. Fifteen of these patients were treated with one or more biologic agents: 14 received rituximab (RTX), 6 received anti-tumor necrosis factor (anti-TNF) therapy (5 treated with anti-TNF agent prior to RTX). Four RTX-treated patients were not receiving additional immunosuppressive therapy at the time of PML onset, other than an antimalarial drug and/or low-dose glucocorticoids; all others who were receiving a biologic agent were also receiving one or more synthetic disease-modifying agents. All but 1 patient receiving a biologic agent had at least 1 potential confounding factor for the diagnosis of PML. The remaining 19 confirmed cases of PML among ARD patients were treated with synthetic disease-modifying antirheumatic drugs only, 14 of whom had received an alkylating agent. Conclusion PML has been reported in patients with ARD treated with various immunosuppressive agents. The limitations of this study preclude definitive attribution of causality. While the paucity of confirmed cases recently exposed to anti-TNF therapy suggests a causal relationship is unlikely, a specific signal is emerging with regard to rituximab and PML. Although this is a rare adverse event associated with RTX therapy, the devastating nature of PML mandates continued vigilance, particularly in patients with current or prior exposure to an alkylating agent. Copyright © 2012 by the American College of Rheumatology.

Theanine (n-ethylglutamic acid), a non-proteinaceous amino acid component of green and black teas, has received growing attention in recent years due to its reported effects on the central nervous system. It readily crosses the blood-brain barrier where it exerts a variety of neurophysiological and pharmacological effects. Its most well-documented effect has been its apparent anxiolytic and calming effect due to its up-regulation of inhibitory neurotransmitters and possible modulation of serotonin and dopamine in selected areas. It has also recently been shown to increase levels of brain-derived neurotrophic factor. An increasing number of studies demonstrate a neuroprotective effects following cerebral infarct and injury, although the exact molecular mechanisms remain to be fully elucidated. Theanine also elicits improvements in cognitive function including learning and memory, in human and animal studies, possibly via a decrease in NMDA-dependent CA1 long-term potentiation (LTP) and increase in NMDA-independent CA1-LTP. Furthermore, theanine administration elicits selective changes in alpha brain wave activity with concomitant increases in selective attention during the execution of mental tasks. Emerging studies also demonstrate a promising role for theanine in augmentation therapy for schizophrenia, while animal models of depression report positive improvements following theanine administration. A handful of studies are beginning to examine a putative role in attention deficit hyperactivity disorder, and theoretical extrapolations to a therapeutic role for theanine in other psychiatric disorders such as anxiety disorders, panic disorder, obsessive compulsive disorder (OCD), and bipolar disorder are discussed. © W. S. Maney & Son Ltd 2014.

Duffy M.J.,Park University
Medical Principles and Practice | Year: 2013

Tumor markers are playing an increasingly important role in cancer detection and management. These laboratory-based tests are potentially useful in screening for early malignancy, aiding cancer diagnosis, determining prognosis, surveillance following curative surgery for cancer, up front predicting drug response or resistance, and monitoring therapy in advanced disease. Clinically useful markers include fecal occult blood testing in screening for early colorectal cancer, carcinoembryonic antigen in the management of patients with colorectal cancer, both α-fetoprotein and human chorionic gonadotrophin in the management of patients with non-seminomatous germ cell tumors, CA 125 for monitoring therapy in patients with ovarian cancer, estrogen receptors for predicting response to hormone therapy in breast cancer, human epidermal growth factor receptor 2 for the identification of women with breast cancer likely to respond to trastuzumab (Herceptin) and KRAS mutational status for identifying patients with advanced colorectal cancer likely to benefit from treatment with the anti-epidermal growth factor receptor antibodies, cetuximab and panitumumab. Although widely used, the value of prostate-specific antigen screening in reducing mortality from prostate cancer is unclear. Copyright © 2012 S. Karger AG, Basel.

The aim of this study was to examine the effect of blocking Toll-like receptor 2 (TLR2) in rheumatoid arthritis (RA) synovial cells. RA synovial tissue biopsies, obtained under direct visualization at arthroscopy, were established as synovial explant cultures ex vivo or snap frozen for immunohistology. Mononuclear cell cultures were isolated from peripheral blood and synovial fluid of RA patients. Cultures were incubated with the TLR1/2 ligand, Pam3CSK4 (200 ng, 1 and 10 μg/ml), an anti-TLR2 antibody (OPN301, 1 μg/ml) or an immunoglobulin G (IgG) (1 μg/ml) matched control. The comparative effect of OPN301 and adalimumab (anti-tumour necrosis factor alpha) on spontaneous release of proinflammatory cytokines from RA synovial explants was determined using quantitative cytokine MSD multiplex assays or ELISA. OPN301 penetration into RA synovial tissue explants cultures was assessed by immunohistology. Pam3CSK4 significantly upregulated interleukin (IL)-6 and IL-8 in RA peripheral blood mononuclear cells (PBMCs), RA synovial fluid mononuclear cells (SFMCs) and RA synovial explant cultures (P < 0.05). OPN301 significantly decreased Pam3CSK4-induced cytokine production of tumour necrosis factor alpha (TNF-α), IL-1β, IL-6, interferon (IFN)-γ and IL-8 compared to IgG control in RA PBMCs and SFMCs cultures (all P < 0.05). OPN301 penetration of RA synovial tissue cultures was detected in the lining layer and perivascular regions. OPN301 significantly decreased spontaneous cytokine production of TNF-α, IL-1β, IFN-γ and IL-8 from RA synovial tissue explant cultures (all P < 0.05). Importantly, the inhibitory effect of OPN on spontaneous cytokine secretion was comparable to inhibition by anti-TNFα monoclonal antibody adalimumab. These findings further support targeting TLR2 as a potential therapeutic agent for the treatment of RA.

Agency: NSF | Branch: Standard Grant | Program: | Phase: ANTARCTIC EARTH SCIENCES | Award Amount: 168.09K | Year: 2014

This project will involve examination of Glossopteridales, fossil plants from Upper Permian deposits, in samples from the central Transantarctic Mountains and Southern Victoria Land, Antarctica. The glossopterids are an important fossil group because they are possible ancestors to the flowering plants. Permian sedimentary rocks (295-270 Ma before present) are important because they record a time of rapid biotic change, as the Late Paleozoic Age ended and the Mesozoic greenhouse environment began. The proposed research will rely entirely on specimens collected during recent field excursions to the central Transantarctic Mountains (CTM; 2010?2011) and southern Victoria Land (SVL; 2012?2013). Only a few of the specimens have been studied, but already have yielded anatomically well-preserved glossopterids with a complete pollen cone, which has never been found before. Additionally, several seed-bearing structures, which have never before been observed in Antarctica, have been found in both CTM and SVL. The project will allow comparison of whole-plant fossil glossopterids from the CTM with other paleo-latitudes, and will document the floral diversity within and between two depositional basins (CTM & SVL) during a time of global change, with the overall goal of linking environmental changes with fossil morphology.

Broader impacts:
The Broader Impacts of this project will include mentoring undergraduates in research projects, at an institution with a substantial minority enrollment. Public outreach will focus on involving middle/high school students through the ?Expanding Your Horizons? programs in Kansas and Missouri, as well as interactive presentations at schools in the Kansas City Area. The lead PI is an early-career scientist at an institution that serves minorities.

Solid electrolytes compositions, methods of making the solid electrolytes, and methods of using the solid electrolytes in batteries and other electrochemical technologies are disclosed. The method of producing a solid electrolyte comprises (a) ball milling Na2CO3, SiO2, NH4H2PO4, a zirconium source, and a dopant to produce a ball milled powder; (b) calcining the ball milled powder to produce a calcined powder; and (c) sintering the calcined powder to produce a solid electrolyte. The zirconium source for the solid electrolyte may be ZrO2. The dopant for the solid electrolyte may be AI2O3, Fe2O3, Sb2O3, Yb2O3, or Dy2O3.

Park University | Date: 2015-05-06

The current invention provides novel nitinol alloys, particularly, nitinol alloys containing a third metallic element referred to as ternary nitinol alloys. Accordingly, the current invention provides nitinol alloys including, but not limited to, Nickel-Titanium-Chromium (NiTiCr) and Nickel-Titanium-Tantalum (NiTiTa). The current invention also provides implants manufactured from the ternary nitinol alloys. The implants comprise the ternary nitinol alloys and are, optionally, surface treated to promote anti-thrombogenicity and biocompatibility, for example, through magnetoelectropolishing (MEP). Accordingly, the current invention provides nitinol alloys and implants comprising the nitinol alloys that reduce the risk of clotting due to stagnant blood flow, eliminate flushing, and minimize infection and damage to blood vessels.

Loading Park University collaborators
Loading Park University collaborators